{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:47:13Z","timestamp":1785419233196,"version":"3.56.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease which affects 1 in 6,000\u201310,000 live births, caused by loss of the survival motor neuron 1 gene (SMN1). A major focus of therapeutic developments has been on increasing the full-length SMN protein by increasing the inclusion of exon 7 in SMN2 transcripts, enhancing SMN2 gene expression, stabilizing the SMN protein or replacing the SMN1 gene. In June 2017, FDA and EMA have approved the antisense oligonucleotide Nusinersen as the first treatment for all SMA subtypes without age restriction. While prominent treatment effects have been observed in the earlier stages of the disease and in patients up to 15 years of age, there is only limited data from clinical trials in adult SMA patients. First real-world data from neuromuscular clinical centers suggest a therapeutic benefit of nusinersen with a favourable safety profile also in adult SMA patients: in several cases, relevant improvements of motor function is achieved, which might lead to enhanced autonomy in daily life activities and improved quality of life. Systematic follow-up of the motor status with validated instruments is crucial for an adequate monitoring of the therapeutic effects but most of the widely used scales and scores have been developed and evaluated for the pediatric population only. International neuromuscular experts have met in Frankfurt\/Main, Germany in May 2019 to discuss relevant aspects of the diagnostic pathway and patient management in adult SMA. The recommendations and challenges in this patient population are discussed.<\/jats:p>","DOI":"10.3233\/jnd-200534","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T12:44:38Z","timestamp":1591965878000},"page":"523-534","source":"Crossref","is-referenced-by-count":57,"title":["Measuring Outcomes in Adults with Spinal Muscular Atrophy \u2013 Challenges and Future Directions \u2013 Meeting Report"],"prefix":"10.1177","volume":"7","author":[{"given":"V.A.","family":"Sansone","sequence":"first","affiliation":[{"name":"The NEMO Clinical Center, Milan - Neurorehabilitation Unit, University of Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Attarian","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders and ALS, CHU La Timone, Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Delstanche","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Liege, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Catholic University of Rome, Roma, Italy"},{"name":"Department of Woman and Child Health and Public Health, Paediatric Neurology and Neuromuscular Omnicentre Clinical Center, Fondazione Policlinico Universitario A Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lochm\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics and Muscle Disorders, Medical Center \u2013 University of Freiburg, Faculty of Medicine, Freiburg, Germany"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, Canada"},{"name":"Department of Medicine, The Ottawa Hospital, and Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Neuwirth","sequence":"additional","affiliation":[{"name":"Muskelzentrum ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Vazquez-Costa","sequence":"additional","affiliation":[{"name":"Instituto de Investigacion Sanitaria la Fe (IIS La Fe), Neuromuscular Research Unit, Valencia, Spain"},{"name":"Department of Neurology, ALS Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain"},{"name":"Centro de Investigacion Biomedica en Red de EnfermedadesRaras (CIBERER), Valencia, Spain"},{"name":"Department of Medicine, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hagenacker","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"18","key":"10.3233\/JND-200534_ref1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":", Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.3233\/JND-200534_ref2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":", Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.3233\/JND-200534_ref4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":", Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.3233\/JND-200534_ref5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.26756","article-title":", Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy","volume":"61","author":"Elsheikh","year":"2020","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.3233\/JND-200534_ref6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":", Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"issue":"3","key":"10.3233\/JND-200534_ref7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","article-title":", Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.3233\/JND-200534_ref8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":", Observational study of spinal muscular atrophy type 2 and 3: Functional outcomes over 1 year","volume":"68","author":"Kaufmann","year":"2011","journal-title":"Arch Neurol"},{"issue":"11","key":"10.3233\/JND-200534_ref9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":", Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.3233\/JND-200534_ref10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":", Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.3233\/JND-200534_ref11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.3233\/JND-200534_ref12","doi-asserted-by":"crossref","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":", Ambulatory function in spinal muscular atrophy: Age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"10.3233\/JND-200534_ref13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.nmd.2017.07.007","article-title":", 6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction","volume":"27","author":"Pera","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.3233\/JND-200534_ref14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"14","key":"10.3233\/JND-200534_ref15","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: Acohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.3233\/JND-200534_ref16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":", Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.3233\/JND-200534_ref17","first-page":"461","article-title":", [(S)un (M)ay (A)rise on SMA: The hope of a region without spinal muscular atrophy]","volume":"74","author":"Boemer","year":"2019","journal-title":"Rev Med Liege"},{"issue":"7","key":"10.3233\/JND-200534_ref18","doi-asserted-by":"crossref","first-page":"e0201004","DOI":"10.1371\/journal.pone.0201004","article-title":", Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.3233\/JND-200534_ref19","doi-asserted-by":"crossref","first-page":"e0121799","DOI":"10.1371\/journal.pone.0121799","article-title":", Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: An observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.3233\/JND-200534_ref20","doi-asserted-by":"crossref","first-page":"e0156696","DOI":"10.1371\/journal.pone.0156696","article-title":", A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment","volume":"11","author":"Le Moing","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JND-200534_ref22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":", SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"Pechmann","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JND-200534_ref23","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418803246","article-title":", Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"18","key":"10.3233\/JND-200534_ref24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":", Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JND-200534_ref25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":", Revised upper limb module for spinal muscular atrophy: 12 month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.3233\/JND-200534_ref26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.23937","article-title":", Rasch analysis of clinical outcome measures in spinal muscular atrophy","volume":"49","author":"Cano","year":"2014","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.3233\/JND-200534_ref27","first-page":"439","article-title":", [Functional assessment for people unable to walk due to spinal muscular atrophy and Duchenne muscular dystrophy. Translation and validation of the Egen Klassifikation 2 scale for the Spanish population]","volume":"60","author":"Fagoaga","year":"2015","journal-title":"Rev Neurol"},{"issue":"25","key":"10.3233\/JND-200534_ref28","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3109\/09638288.2014.892157","article-title":"The applicability of four clinical methods to evaluate arm and hand function in all stages of spinal muscular atrophy type II","volume":"36","author":"Werlauff","year":"2014","journal-title":"Disabil Rehabil"},{"issue":"2","key":"10.3233\/JND-200534_ref29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JND-180325","article-title":", Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients","volume":"5","author":"Lochmuller","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.3233\/JND-200534_ref30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinph.2018.11.009","article-title":", Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy","volume":"130","author":"Gunther","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"5","key":"10.3233\/JND-200534_ref31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","article-title":", Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients","volume":"27","author":"Rouault","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-200534_ref32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3389\/fneur.2019.01166","article-title":", Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy","volume":"10","author":"Kizina","year":"2019","journal-title":"Front Neurol"},{"issue":"5","key":"10.3233\/JND-200534_ref33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00234-019-02189-x","article-title":", Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy","volume":"61","author":"Oldenburg","year":"2019","journal-title":"Neuroradiology"},{"issue":"5","key":"10.3233\/JND-200534_ref34","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1017\/S0317167100014943","article-title":", The CNDR: Collaborating to translate new therapies for Canadians","volume":"40","author":"Korngut","year":"2013","journal-title":"Can J Neurol Sci"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-200534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:31Z","timestamp":1777506571000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-200534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":32,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jnd-200534","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}